Dr. Johnston has been studying neurodegenerative disease for the last 20 years, starting with her work with Dr. R. Kopito at Stanford which resulted in the discovery of Aggresomes. At Elan Pharmaceuticals, Dr. Johnston studied protein folding and cellular proteostasis for basic research and drug discovery for PD. In addition to VP Head of Exploratory Research, Dr. Johnston also identified small molecule therapeutics for Parkin E3 ligase, reported the first high resolution crystal structure of the Parkin protein, and determined Parkin functions as a new category of ligase. Presently, Dr. Johnston is Co-Founder and CEO of NysnoBio, a Biotech company focused on the modulation of the Parkin enzyme pathway for critical unmet medical needs in Neurology and Oncology.
Co-PI (Core Leadership)
Jennifer Johnston, PhD
NysnoBio
Dr. Johnston has been studying neurodegenerative disease for the last 20 years, starting with her work with Dr. R. Kopito at Stanford which resulted in the discovery of Aggresomes. At Elan Pharmaceuticals, Dr. Johnston studied protein folding and cellular proteostasis for basic research and drug discovery for PD. In addition to VP Head of Exploratory Research, Dr. Johnston also identified small molecule therapeutics for Parkin E3 ligase, reported the first high resolution crystal structure of the Parkin protein, and determined Parkin functions as a new category of ligase. Presently, Dr. Johnston is Co-Founder and CEO of NysnoBio, a Biotech company focused on the modulation of the Parkin enzyme pathway for critical unmet medical needs in Neurology and Oncology.
